Compare GRFS & BXSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GRFS | BXSL |
|---|---|---|
| Founded | 1940 | 2018 |
| Country | Spain | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 6.4B |
| IPO Year | 2006 | N/A |
| Metric | GRFS | BXSL |
|---|---|---|
| Price | $8.81 | $25.82 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 8 |
| Target Price | $10.15 | ★ $29.13 |
| AVG Volume (30 Days) | 442.6K | ★ 2.1M |
| Earning Date | 07-28-2022 | 02-25-2026 |
| Dividend Yield | 1.56% | ★ 11.81% |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.64 | ★ 2.66 |
| Revenue | ★ $8,821,017,248.00 | $1,413,784,000.00 |
| Revenue This Year | $5.36 | $9.05 |
| Revenue Next Year | $5.15 | $0.28 |
| P/E Ratio | $17.98 | ★ $9.81 |
| Revenue Growth | 7.31 | ★ 10.58 |
| 52 Week Low | $6.19 | $24.85 |
| 52 Week High | $11.14 | $34.64 |
| Indicator | GRFS | BXSL |
|---|---|---|
| Relative Strength Index (RSI) | 41.49 | 37.33 |
| Support Level | $9.17 | $25.42 |
| Resistance Level | $9.57 | $26.58 |
| Average True Range (ATR) | 0.22 | 0.52 |
| MACD | -0.03 | -0.13 |
| Stochastic Oscillator | 5.13 | 19.08 |
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
Blackstone Secured Lending Fund is a non-diversified, closed-end management investment company. The investment objectives of the company are to generate current income and, to a lesser extent, long-term capital appreciation. The company seeks to achieve its investment objectives by investing in originated loans and other securities, including syndicated loans of private U.S. companies, typically in the form of first lien senior secured and unitranche loans, unsecured and subordinated loans, and other securities.